Saireito (114) Increases IC50 and Changes T-Cell Phenotype When Used in Combination with Prednisolone Therapy in Human Peripheral Blood Mononuclear Cells

Figure 3

Dot plot and cell positive rate of CD4⁺ T cells in the PBMCs after PSL and 114 treatments. (a) Dot plot of CD4⁺ T cells in the PBMCs stimulated by ConA after PSL and 114 treatments (indicated in the square). Vertical axis: PerCP-Cy5-5A; horizontal axis: FSC-A. The inside of the square frame was CD4⁺ T cells, and the ratio was calculated by the number of CD4 stained cells / lymphocyte count  100. (b) Ratio of CD4⁺ T cells in PBMCs after PSL and 114 treatments. Each treatment was compared to its respective blank using Dunnett’s multiple comparisons test (; ). The PSL monotherapy group and the PSL + 114 combination therapy groups were compared using the Tukey–Kramer multiple comparison test (mean + SD, n = 6). ConA: concanavalin A, PBMCs: peripheral blood mononuclear cells, PSL: prednisolone, and 114: saireito.

(a)

(b)